Videos

Paolo Silva, MD, speaks on the effect of diabetic retinopathy lesion location and long-term risk of progression

Barry Kuppermann, MD, PhD, director of the Gavin Herbert Eye Institute at the University of California Irvine, speaks about his ARVO poster presentation

Dr. Marion Munk examines the Phase 2/3 clinical trial of high-dose aflibercept (8 mg) in diabetic macular oedema, presenting key outcomes and clinical implications of the data.

Dr. Marion Munk reviews the Phase 3 clinical trial of high-dose aflibercept (8 mg) in neovascular AMD, emphasizing how this new therapy could alleviate the treatment burden for patients while providing superior outcomes.

Qinqin Zhang, PhD, presented on a deep learning model for GA segmentation at this year's ARVO meeting

At this year's ARVO meeting, Ash Abbey, MD, presented 36-month data from the GALE study of pegcetacoplan

Antonio Filipe Macedo, OD, MSc, PhD, speaks about his ARVO presentation on vision-related activity difficulties in patients with neovascular age-related macular degeneration

New research findings presented at this year's ARVO meeting compare two groups of paediatric patients in Nepal

At this year's ARVO meeting, new data from the BLINK2 study show axial growth rates after discontinuing soft multifocal contact lens wear

Age of vision loss onset has a stark impact on patients’ auditory processing and sensory substitution

Dr Richard Lindstrom speaks about the future of dry eye and shares pearls for young eye surgeons

David Lubeck, MD, talks about the biggest surprises from ASCRS in the glaucoma space